Veracyte, Inc. announced new data showing that its whole-genome sequencing (WGS)-based platform for minimal residual disease (MRD) testing detected cancer in patients treated for muscle-invasive bladder cancer (MIBC).
The molecular cytogenetics market was valued at approximately USD 2.5 billion in 2023 and is projected to expand significantly, registering a compound annual growth rate (CAGR) of 10.1% from 2024 to 2032.
MLO invites you to ask questions about anything related to teamwork, leadership and personal growth in our new article series, Coaching Corner with Patty J. Eschliman, MHA, MLS(ASCP), DLM, CPC.
